BAXBAXHealthcare · Medical Instruments & Supplies

BAX Stock Forecast: Baxter International, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$25
−0.02% on the day

The 15 Wall Street analysts covering Baxter International, Inc. hold a median 12-month price target of $26 — +2.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 94 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$13.1B
Ticker Nerd rank
94/ 100
Median analyst target
$26
Analysts covering
15
Revenue$3.0B+5.3% y/y
Operating income$217.0M
Net income$126.0M
Free cash flow$166.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.6%
1M
+3.6%
YTD
+33.0%
1Y
+46.0%
From 52W high
−10.4%
From 52W low
+60.8%
$16
$28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Baxter International, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
94/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
95
Value
95
Revisions
91
Issuance
88
Volatility
70
Growth
64
Momentum
60
Quality
50

Accruals (95): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (50): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

BAX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BAX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30$35$40Jan 26Apr 26Jul 26Oct 26BAXHigh $40Median $26Low $23

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
2
Buy
12
Hold
1
Sell
$23
Low
$26
Median
$40
High

The green dot is the last close — the median target sits +2.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 11 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
9 Nov 2026BarclaysMaintainsUnderweight$20 → $23
30 Oct 2026JP MorganMaintainsNeutral$26 → $25
30 Oct 2026Wells FargoMaintainsEqual-Weight$23 → $25
7 Oct 2026BarclaysInitiatesUnderweight—
5 Oct 2026CitigroupMaintainsNeutral$28 → $27
31 July 2026CitigroupUpgradeNeutral$17 → $28
31 July 2026StifelMaintainsHold$24 → $28
31 July 2026TD CowenMaintainsHold$24 → $29
31 July 2026Wells FargoMaintainsEqual-Weight$19 → $23
28 July 2026StifelMaintainsHold$19 → $24
28 July 2026UBSMaintainsNeutral$19 → $25
27 July 2026TD CowenMaintainsHold$20 → $24
15 July 2026Goldman SachsMaintainsNeutral$19 → $21
6 July 2026Evercore ISI GroupMaintainsOutperform$22 → $24
28 May 2026CitigroupDowngradeSell—
4 May 2026BarclaysMaintainsOverweight—
6 Apr 2026Evercore ISI GroupMaintainsOutperform—
11 Mar 2026CitigroupMaintainsNeutral—
17 Feb 2026Goldman SachsMaintainsNeutral—
13 Feb 2026BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for BAX.

Market Radar

This page is one stock. Monday covers all of them.

BAX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

BAX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Baxter International, Inc. returned +46.0% against +6.9% for the S&P 500, dividends included.

BAX vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160Jan 26Apr 26Jul 26Oct 26BAXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BAX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+2.8%
Analysts raising
13
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1.2×

Cheaper than 62% of US stocks

Price / book
2.1×

Cheaper than 42% of US stocks

EV / EBITDA
10.9×

Cheaper than 52% of US stocks

Growth & margins
Revenue growth (YoY)
5.0%

Higher than 41% of US stocks

Earnings growth (YoY)
—
Gross margin
34.9%

Higher than 42% of US stocks

Operating margin
7.6%

Higher than 59% of US stocks

Net margin
−6.2%

Higher than 23% of US stocks

Returns & dividend
Return on equity
−9.0%

Higher than 37% of US stocks

Return on assets
2.7%

Higher than 62% of US stocks

Dividend yield
0.2%

Higher than 2% of US dividend payers

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Baxter International, Inc. has a market value of $13.1B and an enterprise value of $19.9B.

  • Revenue in the twelve months to 30 June 2026: $11.5B. The latest quarter grew 5.3% year on year.

  • Net income over the same four quarters: −$1.1B, a −9.3% net margin.

  • Diluted earnings per share, trailing twelve months: −$2.07.

  • Free cash flow in the twelve months to 30 June 2026: $812.0M, after $504.0M of capital spending.

  • Baxter International, Inc. spent $184.0M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 517.0M.

  • forward P/E: 12.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.15%.

  • Baxter International, Inc. employs 37,500 people — $306K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

BAX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
BAXBaxter International, Inc.$13.1B94
SOLVSolventum Corp.$14.7B76
COOThe Cooper Cos., Inc.$11.5B71
ALGNAlign Technology, Inc.$11.1B83
RGENRepligen Corp.$10.4B87
AVTRAvantor, Inc.$10.1B83
ATRAptarGroup, Inc.$9.2B62

Take a look at BAX’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Baxter International, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about BAX

What is the BAX stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Baxter International, Inc. have a median 12-month price target of $26, with estimates ranging from $23 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BAX stock a buy right now?

Of the 15 analysts covering Baxter International, Inc., 2 rate it a Buy, 12 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Baxter International, Inc. 94 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BAX?

As at 21 Nov 2026, Baxter International, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (95 of 100).

Will BAX stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +2.4% from the last close, and Ticker Nerd's factor model ranks Baxter International, Inc. 94 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BAX stock forecast for 2030?

No analyst covering Baxter International, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BAX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $40 over the next 12 months.

How has BAX stock performed over the past year?

Baxter International, Inc. returned +46.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Baxter International, Inc. do?

Baxter International Inc. is a global healthcare company focused on providing essential medical products and technologies used in hospitals, clinics, surgery centers, pharmacies, and home-care settings. Baxter International Inc. develops and supplies infusion systems, sterile intravenous solutions, injectable pharmaceuticals, parenteral nutrition therapies, advanced surgery products, patient monitoring and diagnostic technologies, smart beds, and respiratory care devices.

Company

About Baxter International, Inc.

Baxter International Inc. is a global healthcare company focused on providing essential medical products and technologies used in hospitals, clinics, surgery centers, pharmacies, and home-care settings. Baxter International Inc. develops and supplies infusion systems, sterile intravenous solutions, injectable pharmaceuticals, parenteral nutrition therapies, advanced surgery products, patient monitoring and diagnostic technologies, smart beds, and respiratory care devices. The company also supports renal and acute care through therapies and connected solutions that help clinicians deliver treatment across a wide range of care environments. Its portfolio is designed to support everyday healthcare delivery, from critical care and procedural settings to long-term and ambulatory care. Baxter International Inc. plays an important role in the medical technology market by supplying products that are widely used in routine treatment, life-sustaining therapy, and hospital infrastructure.

CEO Mr. Andrew P. Hider · 37,500 employees · United States · https://www.baxter.com